Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

Zelasudil

Source date not recordedAnalyse record ↗

Selective ROCK2 inhibitor after completion of a Phase 2a idiopathic-pulmonary-fibrosis study, with further development under evaluation.

Modality
oral selective ROCK2 inhibitor
Availability (US)
Phase 2a IPF study completed; further fibrotic-indication development and partnering under evaluation
Biomarkers
forced vital capacity; diffusing capacity; quantitative lung fibrosis imaging; PRO-C3; CA19-9; CA-125; adverse events
Hallmark targeted
extracellular-matrix remodeling, fibrosis, altered intercellular communication
Kind
investigational drug
Clinical trials
NCT05570058 — Phase 2, Active, not recruiting on August 23, 2024 registry update; company reports the Phase 2a study completed in 2025